Why the study?
Does Transcatheter Aortic-Valve Replacement (TAVR) reduce death and hospitalization in appropriately selected patients with severe aortic stenosis who are not suitable candidates for surgery?
Does Transcatheter Aortic-Valve Replacement (TAVR) reduce death and hospitalization in appropriately selected patients with severe aortic stenosis who are not suitable candidates for surgery?
TAVR provides sustained reduction in death and hospitalization, along with symptomatic and hemodynamic improvements at 2 years in inoperable patients with severe aortic stenosis.
Supports TAVR in inoperable severe AS; leaves open need for randomized confirmation of sustained benefits.
Among appropriately selected patients with severe aortic stenosis who were not suitable candidates for surgery, TAVR reduced the rates of death and hospitalization, with a decrease in symptoms and an improvement in valve hemodynamics that were sustained at 2 years of follow-up. The presence of extensive coexisting conditions may attenuate the survival benefit of TAVR. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).
No takes yet. Share an insight, caveat, or question.
Makkar et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: